CSV April 5, 2023 through April 5, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NALOXONE HYIM		*Revision*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROCHLORIDE INJECTION	PURITIES/*Limit of 2,2?-Bisnaloxone*	*Bulletin (Official September 01, 2020)*						Change [Note—The relative retention times for naloxone and 2,2?-bisnaloxone (4,5?:4?,5?-diepoxy-3,3?,14,14?-tetrahydroxy-17,17?-bis(prop-2-enyl)-2,2?-bimorphinanyl-6,6?-dione) are 1.0 and 2.8, respectively.] to: [Note—The relative retention times for naloxone and 2,2?-bisnaloxone (4,5?:4?,5??-diepoxy-3,3?,14,14?-tetrahydroxy-17,17?-bis(prop-2-enyl)-2,2?-bimorphinanyl-6,6?-dione) are 1.0 and 2.8, respectively.]
FENTANYL	*Assay*	*USP43–NF38*	1849	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Procedure*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CITRATE INJECTION								Change $CD(r_U/r_S)$ in which 336.48 and 528.59 are the molecular weights to: $CD(r_U/r_S)$ in which 336.48 and 528.60 are the molecular weights
TRYPSIN	CHEMICAL INFORMATION	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Change $C_{1012}H_{1555}N_{279}O_{324}S_{14}$ 23,293 (for bovine ?-Trypsin) to: $C_{1012}H_{1585}N_{279}O_{324}S_{14}$ 23,293 (for bovine ?-Trypsin)
TIAGABINE HY ASSAY/		*USP43–NF38*	4365	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROCHLORID E	*Procedure*							*solution*: Change Transfer suitable volumes of the *Standard stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. to: 0.1 mg/mL of USP Tiagabine Hydrochloride RS and 0.04 mg/mL of butylparaben in *Diluent* prepared as follows. Transfer suitable volumes of the *Standard stock solution* and *Internal*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard solution into a suitable volumetric flask and dilute with *Diluent* to volume. AND In the *Sample solution*: Change Transfer suitable volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume. to: 0.1 mg/mL of Tiagabine Hydrochloride and 0.04 mg/mL of butylparaben in *Diluent*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prepared as follows. Transfer suitable volumes of the *Sample stock solution* and *Internal standard solution* into a suitable volumetric flask and dilute with *Diluent* to volume.
AMIODARONE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Amiodarone Related Compound H RS: Change 2-Chloro-*N*,*N*-diethylethanamine. $C_6H_{14}ClN$ 135.64 to: 2-Chloro-*N*,*N*-diethylethanamine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride. $C_6H_{14}ClN \cdot HCl$ 172.09
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION	1. PRELIMINARY ASSESSMENT	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In paragraph 4 of *1.4 Choosing an apparatus*: Change peak vessels to: apex vessels
PLASTIC MATERIALS OF CONSTRUCTION	POLYAMIDE 6	*First Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Related Substances*/*Chromatographic system*/*Column*: Change 0.25-mm × 0.25-µm; phase G25 to: 30-m × 0.25-mm; 0.25-µm phase G25
ORBIFLOXACIN	*Related compounds*	*USP43–NF38*	3275	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Procedure*: Change $20{,}000(C_S)(r_i/r_S)(1/F)$ in which C_S is the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								concentration, in mg per mL, of orbifloxacin in the *Standard solution*; r_i is the peak area response for each impurity obtained from the *Test solution*; r_S is the peak area response for the orbifloxacin peak obtained from the *Standard solution*; and *F* is the relative response factor for each impurity, as presented in *Table 1*. to: $20{,}000(C_S)(r_i/r_S)(1/F)(1/W)$ in which C_S is the concentration, in mg per mL, of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								orbifloxacin in the *Standard solution*; r_i is the peak area response for each impurity obtained from the *Test solution*; r_S is the peak area response for the orbifloxacin peak obtained from the *Standard solution*; *F* is the relative response factor for each impurity, as presented in *Table 1*; and *W* is the sample weight taken to prepare the *Test solution* (mg).
GOSERELIN ACETATE	IM PUR ITIES/*Organic Impurities:*	*Interim Revision Announcement (Official May 01,*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Table 1*: Change Goserelinare to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Related Compounds	*2020)*						Goserelin
AMLODIPINE AND ATORVASTATIN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	265	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64
RESIDUAL SOLVENTS	*Appendix 3*	*Interim Revision Announcement (Official December 01, 2020)*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the denominator in the equation in the final paragraph: Change at mK$^{?1}$ to: atm K$^{?1}$
RESIDUAL SOLVENTS—VERIFICATION OF COMPENDIAL PROCEDURES AND VALIDATION OF ALTERNATIVE PROCEDURES	VERIFICATION OF COMPENDIAL PROCEDURES	*USP43–NF38*	8404	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Limit Procedures: Procedure A and Procedure B/Verification when solvents likely to be present (LTBP) are not known/Specificity*: Change or acetonitrile

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and *cis* -dichloroethene to: or methylisobutylketone and *cis* -dichloroethene
MIRTAZAPINE TABLETS	ADDITIONAL REQUIREMENTS	*USP43–NF38*	2978	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>/USP Mirtazapine Resolution Mixture RS: Change This resolution mixture contains approximately 0.1% w/w each of the following: Impurity A: 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine 2-oxide.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Mirtazapine. Impurity A: 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine 2-oxide.
EFAVIRENZ TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	1591	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the footnotes in *Table 2*: Change [d](*S,E*)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one. [e](*S,Z*)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one. to: [d](*S,Z*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one. [e](*S,E*)-6-Chloro-4-(pent-3-en-1-ynyl)-4-(trifluoromethyl)-2*H*-3,1-benzoxazin-2-one.
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	414	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Atorvastatin Related Compound C RS: Change Difluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Calcium (3*R*,5*R*)-7-[2,3-Bis(4-fluorophenyl)-5-isopropyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as Difluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. AND In USP Atorvastatin Related Compound D

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS: Change Epoxide impurity, or 3-(4-fluorobenzoyl)-2-isobutyryl-3-phenyl-oxirane-2-carboxylic acid phenylamide. to: 3-(4-Fluorobenzoyl)-2-isobutyryl-*N*,3-diphenyloxirane-2-carboxamide; Also known as Epoxide impurity, or 3-(4-fluorobenzoyl)-2-isobutyryl-3-phenyl-oxirane-2-carboxylic acid phenylamide. AND In USP Atorvastatin Related Compound E RS: Change 3*S*,5*S* Enantiomer, or (3*S*,5*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. $C_{66}H_{68}CaF_2N_4O_{10}$ 1155.34 to: Calcium (3*S*,5*S*)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as 3*S*,5*S* Enantiomer, or (3*S*,5*S*)-7-[3-(phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. $C_{66}H_{68}CaF_2N_4O_{10}$ 1155.38 AND In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64 AND In Atorvastatin Related Compound I RS: Change 654.81 to: 654.82
PLASTIC PACKAGING SYSTEMS FOR PHARMACEUTICAL USE	SCOPE/*Table 1*	*First Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Change If light protection is necessary[c] to: If light protection is necessary

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Change Row 11 Chemical Suitability for Use Assessment Risk-based testing Risk-based testing to: Chemical Suitability for Use Assessment Risk-based testing Risk-based testing Functionality
FENOPROFEN CALCIUM	CHEMICAL INFORMATION	*USP43–NF38*	1843	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Change [53746-45-5]; to: [71720-56-4];
MEBENDAZOLE ORAL SUSPENSION	*Identification*	*USP43–NF38*	2744	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Change Mix a quantity of Oral Suspension, equivalent to about 200 mg of mebendazole, with 20 mL of a mixture of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloroform and 96 percent formic acid (19:1). Proceed as directed for *Identification* under *Mebendazole Tablets*, beginning with “Warm the suspension on a water bath for a few minutes.” The specified result is obtained. to: Mix a quantity of Oral Suspension, equivalent to about 200 mg of mebendazole, with 20 mL of a mixture of chloroform and 96 percent formic acid (19:1). Warm the suspension

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								on a water bath for a few minutes, cool, and filter through a medium-porosity, sintered-glass filter. Apply 10 ?L of this solution and 10 ?L of a *Standard solution* of USP Mebendazole RS in a mixture of chloroform and 96 percent formic acid (19:1) containing 10 mg per mL to a suitable thin-layer chromatographic plate (see *Chromatography* <621>) coated with a 0.25-mm layer of chromatographic silica gel mixture.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Allow the spots to dry, and develop the chromatogram in a solvent system consisting of a mixture of chloroform, methanol, and 96 percent formic acid (90:5:5) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, allow the solvent to evaporate, and examine the plate under shor t-wavelength UV light: the R_F value of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								principal spot obtained from the *Test solution* corresponds to that obtained from the *Standard solution*.
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION	6. ACCEPTANCE CRITERIA	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In Row 1 of *Table 5* and *Table 6*: Align Times with Acceptance Criteria
ATORVASTATIN CALCIUM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	418	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Atorvastatin Related Compound H RS: Change 540.62 to: 540.64
PLASTIC MATERIALS OF CONSTRUCTION	INTRODUCTION	*First Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	Delete An example of an extractable elements testing strategy is provided in *Evaluation of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Plastic Packaging Systems and Their Materials of Construction with Respect to Their User Safety Impact ?1661?.
TIAMULIN	IMPURITIES/*Organic Impurities*	*USP43–NF38*	4368	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In the equation in *Analysis*: Change Result = (r_U/r_T) x 100 to: Result = (r_U/r_T) x *D* x 100 AND Add *D* = dilution factor for the *Sample solution*, 0.01
MIRTAZAPINE	ADDITIONAL REQUIREMENTS	*USP43–NF38*	2976	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>/USP Mirtazapine Resolution Mixture RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								This resolution mixture contains approximately 0.1% w/w each of the following: Impurity A: 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine 2-oxide. to: Mirtazapine. Impurity A: 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine 2-oxide.
GUIDELINES ON THE ENDOTOXINS	METHOD SUITABILITY	*USP43–NF38*	7665	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In Row 2 of Column 3 of *Table 3*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TEST								Change hydrochloride to: hydrochloric acid AND In paragraph 2 of *Method Suitability Testing/ Common Test Interferences*: Change hydrochloride to: hydrochloric acid
THE APPLICATION OF MOISTURE VAPOR TRANSMISSION RATES FOR SOLID ORAL DOSAGE FORMS IN PLASTIC PACKAGING SYSTEMS	EQUIVALENCY AND APPLICATION OF MVTR DETERMINATION METHOD	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In *Application*/paragraph 3: Change ?0.8/day/tablet to: ?0.8 mg/day/tablet
THE DISSOLUTION	2. METHOD DEVELOPMENT	*Second Supplement to*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In paragraph 2 of *2.4 Study*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROCEDURE: DEVELOPMENT AND VALIDATION		*USP43–NF38*						*Design/2.4.1 Time Points*: Change *Assessment of Drug Product Performance—Bioavailability, Bioequivalence, and Dissolution* ?1090?. to: *Assessment of Solid Oral Drug Product Performance and Interchangeability, Bioavailability, Bioequivalence, and Dissolution* ?1090?.
HYDROXYPROPYL BETADEX	CHEMICAL INFORMATION	*USP43–NF38*	5818	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change [94035-02-6]. to: [128446-35-5].
APREPITANT CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	362	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Test 3/Apparatus 2*: Change peak vessels. to: apex vessels.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION	POLYETHYLENE TEREPHTHALATE BOTTLES AND POLYETHYLENE TEREPHTHALATE G CONTAINERS	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/ Extracting media*: Change *50 percent alcohol*: Dilute 125 mL of alcohol with water to 238 mL, and mix. *25 percent alcohol*: Dilute 125 mL of *50 percent alcohol* with water to 250 mL, and mix. *General procedure*: [Note— Use an *Extracting medium* of *50 percent alcohol* for PET bottles and *25 percent alcohol* for PETG bottles.]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Purified Water*: See monograph. *50 percent alcohol*: Dilute 125 mL of alcohol with water to 238 mL, and mix. *25 percent alcohol*: Dilute 125 mL of *50 percent alcohol* with water to 250 mL, and mix. *n-Heptane* *General procedure*: [Note— Use an *Extracting medium* of *50 percent alcohol* for PET bottles and *25 percent alcohol* for PETG bottles.] AND In four instances in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/*Heavy Metals*: Change *Extracting media* to: *Purified Water Extracting medium* AND In *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol*/*Ethylene Glycol*/*Test solution*: Change *Extracting media* to: *Purified Water Extracting medium* AND In *Heavy*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Ethylene Glycol/ Proce dure/paragraph 1: Change *Extracting media* extract *Extracting medium* to: *Purified Water Extracting medium* AND In *Heavy Metals, Total Terephthaloyl Moieties, and Ethylene Glycol/Ethylene Glycol/ Proce dure*/paragraph 2: Change using as the blank the solution from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Extracting media*: the absorbance of the solution to: using *Purified Water Extracting medium* as the blank: the absorbance of the solution
CLOMIPHENE CITRATE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In USP Clomiphene Related Compound A RS: Change (*E,Z*)-2-[4-(1,2-Diphenylethyl)phenoxy]-*N,N*-diethylethanamine hydrochloride. to: (*E,Z*)-2-[4-(1,2-Diphenylethenyl)phenoxy]-*N,N*-diethylethanamine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride.
GELATIN	SPECIFIC TESTS/*Sulfur Dioxide*	*Harmonization (Official May 01, 2020)*	5783	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In three instances in *Analysis*: Change 0.1 M sodium hydroxide to: *Titrant* AND In the equation: Change *M* to: *N* AND In the variable definition list: Change *M* = actual molarity of the *Titrant* (mol/L) to: *N* = actual normality of the *Titrant*
NATEGLINIDE	CHEMICAL INFORMATION	*USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	This erratum applies to the USP-NF ONLINE platform only.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	CONTAMINANTS	*USP43–NF38*	5378	30-Oct-2020	1-Nov-2020	*NA*	*NA*	See http://uspnf.com/nateglinide-err-img-20201030 for correction Change *Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species* and *Absence of Specified Microorganisms <2022>, Test Procedures, Test for Absence of Salmonella Species*: to: *Absence of Specified Microorganisms <2022>, Test Procedures, Test for*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LOSS ON IGNITION	INTRODUCTION	*USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	*Absence of Salmonella Species* and *Test for Absence of Escherichia coli:* In paragraph 3: Change Upon completion of each ignition, cover the crucible, and allow it to cool in a desiccator to room temperature before weighing. to: Upon completion of each ignition, cover the crucible, and allow it to cool in a desiccator to room temperature before weighing accurately.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OXYGEN	IMPURITIES	*USP43–NF38*	3347	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in Medical Gases Assay* ?413? to: *Impurities Testing in Medical Gases* ?413?
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS	ASSAY/ *Procedure*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Buffer A*: Change monobasic potassium phosphate to: monobasic sodium phosphate
PRAZIQUANTEL TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3650	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *For products for veterinary use*/*Apparatus 2*: Change peak vessels to: apex vessels
CELL-BASED ADVANCED THERAPIES AND TISSUE-BASED	ANALYTICAL METHODS	*USP43–NF38*	7400	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *In-Process Control s*/paragraph 2: Change Refer to *Risk*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PRODUCTS								*Assessment* for discussion on critical process parameters (CPP). to: Refer to *Quality Systems* for discussion on critical process parameters (CPP). AND In *Final Product Release Specifications/Dose-Defining Assays* /paragraph 3: Change relay to: rely
VOLUMETRIC APPARATUS	STANDARDS OF ACCURACY	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In paragraph 3: Change and then touched against the wall of the receiving vessel to drain the tips. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and then touched against the wall of the receiving vessel to drain the pipet tip.
OXYGEN 93 PERCENT	IMPURITIES	*USP43–NF38*	3347	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in Medical Gases Assay* ?413? to: *Impurities Testing in Medical Gases* ?413?
GALANTAMINE EXTENDED-RELEASE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In USP Galantamine Hydrobromide Related Compounds Mixture RS: Change Anhydrogalantamine; (4a*S*,8a*S*)-3-Methoxy-11-methyl-9,10,11,12-tetrahydro-4a*H*-benzo[2,3]benz

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ofuro[4,3-*cd*]azepine. $C_{17}H_{19}NO_2$ to: Anhydrogalantamine; (4a*S*,8a*S*)-3-Methoxy-11-methyl-9,10,11, 12-tetrahydro-4a*H* -benzo[2,3]benzofuro[4,3-*cd*]azepine. $C_{17}H_{19}NO_2$ 269.34
GALANTAMINE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	2081	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Test 3*/*Apparatus 2*: Change peak vessels to: apex vessels
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	ADDITIONAL REQUIREMENTS/*Labeling*	*USP43–NF38*	5378	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In footnote 1: Change 1 mg of -alpha tocopheryl acetate to: 1 mg of *all-rac*-alpha tocopheryl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acetate
ANISE OIL	IDENTIFICATION/*A. Chromatographic Identity*	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Acceptance criteria/ Chromatographic similarity*: Change [Note—The chromatogram of the *Standard* is similar to the reference chromatogram provided with the lot of being used.] to: [Note—The chromatogram of the *Standard* is similar to the reference chromatogram provided with the lot of USP Anise Oil RS being used.]
VERAPAMIL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	4604	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Buffer*, *Mobile phase*, and *Chromatographic system*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Proceed as directed in the *Assay*. to: *Buffer* and *Mobile phase*: Prepare as directed in the *Assay*.
METHYLENE BLUE	CHEMICAL INFORMATION	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride; 3,7-Bis(dimethylamino)phenothiazin-5-ium chloride; to: Phenothiazin?5?ium, 3,7?bis(dimethylamino)?, chloride, hydrate (1:1:x); 3,7?Bis(dimethylamino)phenothiazin?5?ium chloride hydrate; [122965?43?9]. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Monohydrate [122965-43-9]. to: Monohydrate [67183?68?0].
CELL-BASED ADVANCED THERAPIES AND TISSUE-BASED PRODUCTS	REGULATIONS AND STANDARDS	*USP43–NF38*	7400	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *Table 5*/Row 8 of Column 2: Change 221 CFR 1271 to: 21 CFR 1271
EVALUATION OF PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION WITH RESPECT TO THEIR USER SAFETY IMPACT	6. APPLICABILITY AND APPLICATION OF <661.1>	*First Supplement to USP43–NF38*	Online	30-Oct-2020	1-Nov-2020	*NA*	*NA*	In *6.2 Application*/*6.2.5 Unaddressed Materials*: Change physiochemical to: physicochemical
MEDICAL AIR	IMPURITIES	*USP43–NF38*	100	30-Oct-2020	1-Nov-2020	*NA*	*NA*	Change *Impurities Testing in Medical Gases Assay* ?413? to: *Impurities*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Testing in Medical Gases ?413?
CEFTIOFUR HYDROCHLORIDE	IM PURITIES/*High Molecular Weight Impurities*	*USP43–NF38*	875	25-Sep-2020	1-Oct-2020	*NA*	*NA*	In *Mobile phase*: Change 10 g/L of electrophoresis grade sodium dodecyl sulfate in *Solution A*. to: 10 g/L of electrophoresis grade sodium dodecyl sulfate in *Solution B*.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15

- …
- Next page Next ›
- Last page Last »